Cases & Deals

  • Home
  • Practices
  • Fred Hutchinson Cancer Research Center defeats IPR petition brought by Miltenyi Biomedicine GmbH

Share

Fred Hutchinson Cancer Research Center defeats IPR petition brought by Miltenyi Biomedicine GmbH

February 2024

Client(s) Fred Hutchinson Cancer Research Center

Jones Day represented patent owner Fred Hutchinson Cancer Research Center, on behalf of exclusive licensee Bristol Myers Squibb, in successfully defeating a patent challenge in an inter partes review (IPR) proceeding brought by petitioners Miltenyi Biomedicine GmbH and Miltenyi Biotec Inc. ("Miltenyi") in the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB). The proceeding involved U.S. Patent No. 9,987,308 related to an adoptive cellular immunotherapy composition. The PTAB ruled in favor of the patent owner by denying institution in September 2023, thereby avoiding a full trial. Miltenyi filed a request for rehearing, which the PTAB denied in February 2024.

Miltenyi Biomedicine GmbH et al v. Fred Hutchinson Cancer Research Center, IPR2023-00760 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.